Big Rock Partners Files Prelim Proxy for Another Deadline Extension on NeuroRX Merger

Big Rock Partners
NeuroRx (PRNewsfoto/NeuroRx)

Big Rock Partners filed a preliminary proxy today with the SEC, asking shareholders to vote for a deadline extension to give the SPAC more time to close a deal.

A precise date for the shareholder vote was not set in the filing, nor was the exact date of the proposed deadline extension. The current deadline for the SPAC to close a merger is April 23, which was the deadline extension Big Rock management had asked shareholders to approve in December around the time the SPAC announced a proposed $500 million business combination with NeuroRx.

Big Rock since then has also faced a potential Nasdaq delisting and an investigation of the NeuroRx deal by a New York law firm. Read more.

Total
0
Shares
Related Posts
Read More

HDL Therapeutics Combining with Swiftmerge Acquisition in $480M Deal

The target is a commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2™ System) for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia. Cholesterol and calcium deposits are the common culprits behind this arterial condition.